Language Select
Varian Logo

Recent News

December 12, 2017
Varian (NYSE: VAR) today announced the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia has selected the Eclipse™ treatment planning system to replace its existing cancer... Read more
December 11, 2017
Varian (NYSE: VAR) today announced that it will report results for the first quarter of fiscal year 2018 after market close on Wednesday, January 24, 2018. The news release will be followed by a... Read more
December 06, 2017
Further expanding the global availability of its new device for cancer treatment, Varian (NYSE: VAR) today announced the Halcyon™ system has received ANVISA registration in Brazil. This... Read more

Recent Blog Posts

Nov 29, 2017 | Spot ON Blog
The potential benefits of proton therapy have yet to be realized. That motivated a group of us to undertake a comprehensive look at the physics and technology powering intensity-modulated proton... Read more
Nov 22, 2017 | Centerline
In 2015, Sarah Cannon, the Cancer Institute of HCA Healthcare, announced a new initiative to create an infrastructure and tools to assess and improve the quality, safety and outcomes across HCA... Read more
Oct 24, 2017 | Centerline
Doctors at the University Hospitals of Geneva (HUG) have begun to utilize the Calypso® GPS for the body® technology to enhance the accuracy of radiotherapy in the treatment of lung cancer.... Read more

Corporate Communications Contacts

Corporate Communications Contacts

Corporate Communications Contacts

Mark Plungy
Director, Public Relations
650.424.5630
[email protected]

Mike Bruff
VP, Investor Relations
1 650 424 5163
[email protected]

Neil Madle
Director, Corporate Communications/Investor Relations, Europe
+44 (0)7786 526 068
[email protected]